No Data
Wells Fargo Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $95
Buy Rating on Intellia Therapeutics Backed by Promising Phase 1 Study and Upcoming Data Presentation
Institutional Owners May Consider Drastic Measures as Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Recent US$92m Drop Adds to Long-term Losses
Intellia Therapeutics to Present New Clinical Data From the Phase 1 Study of Nexiguran Ziclumeran (Nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions
RBC Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $54
Intellia Therapeutics (NTLA) Receives a Buy From RBC Capital